RE: Sp crap13 Dec 2023 11:27
The issue is there are lots of us shareholders who like to moan and complain because it HAS taken so long but now we are at the cusp, when we should be sharing the positivity, its just negativity over all that has come before. I think perhaps the issue is you have no other outlet? I know MrIndia vents to me and others in private, I vent to him, pingu, hedge and more often, again in private. I am frustratued, we all are, we all want vlad to make some progress, but by and large we do it in private because we dont want to put off other potential investors which is what happens when there is only moaning here.
I am not saying your issues over the last 3 years are not valid, I am not saying that my nuts dont throb from the constant kicking. And I need to vent often too, because god knows you cant vent to your wife you have to keep a front, but venting here because of past frustration is just counter productive. As a reality check:
IND = Clinical
Prevail are not dodgy cowboys, they are experienced and know what they are doing and have a proven track record. They have agreed that 2023 was a realistic target for going clinical, if it slips a bit? So be it.
The FDA are the FDA, they are god here. They have reviewed HEMO-CAR-T, they had one issue, they have reviewed the fix and approved it. The issue has been resolved, its there in the RNS, they had ONE PQ run to do which is probably finished. IND RNS could come at any time.
I dont think any of this is controversial, and it makes for a very compelling argument to invest now. But NOBODY, and I mean absolutely nobody is talking about this outside of LSE and even on LSE there is next to zero positive discussion.
I dont need people to tell me what I already know, people not talking about hemo, lack of PR, some deramping on here has ZERO impact on me in terms of deciding to invest more or not. But it sure as hell affects others, so dont be surprised when SP not moving when there is nobody talking about Hemo. Screw the traders, let them miss out, the fact they are not buying in does not slow down or have any impact on IND submission.